Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment-Experienced People Living With Human Immunodeficiency Virus.
Lauren GreenbergLene RyomBastian NeesgaardGilles WandelerTherese StaubMartin GisingerMichael SkollHuldrych F GünthardAlexandra ScherrerCristina MussiniColette SmithMargaret JohnsonStéphane De WitCoca NecsoiChristian PradierFerdinand WitClara LehmannAntonella d'Arminio MonforteJose M MiróAntonella CastagnaVincenzo SpagnuoloAnders SönnerborgMatthew LawJolie HutchinsonNikoloz ChkhartishviliNatalia BolokadzeJan-Christian WasmuthChristoph StephanVani VannappagariFelipe RogattoJosep M LlibreClaudine DuvivierJennifer HoyMark BlochHeiner C BucherAlexandra CalmyAlain Volny AnneAnnegret Pelchen-MatthewsJens D LundgrenLars PetersLoveleen Bansi-MatharuAmanda Mocroftnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2021)
This is the first large, international cohort to assess clinical outcomes on 2DRs. After accounting for baseline characteristics, there was a similar incidence of events on 2DRs and 3DRs. 2DRs appear to be a viable treatment option with regard to clinical outcomes. Further research on resistance barriers and long-term durability of 2DRs is needed.